太极集团晚间公告，公司拟分别拟以现金2,108万元 的价格受让重庆中药材有限公司持有重庆桐君阁中 药批发有限责任公司90%的股权以及以现金235万元的价格受让太极集团重庆涪陵医药有限公司持有桐 君阁中药批发10%股权。本次股权转让均为公司与控股子公司之间进行，不涉及外部股东，不会导致公 司合并报表范围发生变化，不会对公司财务及经营状况产生不利影响。 ...

北京商报讯（记者 郭秀娟 王悦彤） 2月3日，众兴菌业发布公告称，公司召开董事会，通过了《关于受 让控股子公司股权暨关联交易的议案》。公司拟以自有资金725万元受让高博书、刘亮等8名股东合计持 有的四川众兴菌业科技有限公司（以下简称"四川众兴"）29%股权（对应认缴出资1450万元，已实缴 725万元）。本次交易构成关联交易，因其他股东中高博书、刘亮、陶春晖等均为公司关联自然人。此 次股权转让后，众兴菌业将持有四川众兴100%股权，使其成为全资子公司。公司表示，完成本次交易 后，将进一步优化资源整合，提高经营管理效率，对公司的财务状况和经营成果不会产生重大影响。 ...

Core Viewpoint - The company, Yawen Co., Ltd. (002559.SZ), is committed to the development of precision laser processing equipment and has acquired a 38.50% stake in Jiangsu Yawen Aios Laser Technology Co., Ltd. from SM Heavy Industries for a total investment of RMB 4,620,000 [1] Group 1 - The acquisition aims to strengthen the company's position in the precision laser processing equipment sector [1] - The transaction was formalized through a signed share purchase agreement [1]

Core Viewpoint - The company plans to acquire 927,600 shares of Beijing Xinghe Power Aerospace Technology Co., Ltd. for RMB 30 million, representing 0.2143% of Xinghe Power's total share capital [1] Group 1 - The acquisition will involve the company's controlling shareholder and actual controller, Mr. He Shida, who will acquire an additional 1,236,800 shares of Xinghe Power [1] - The transaction will result in a joint investment with related parties, constituting a related party transaction [1] - This transaction does not constitute a major asset reorganization [1]

Core Viewpoint - Company Puhui Co., Ltd. has acquired a 15.28% stake in Xinjiang Qinxiong Technology Co., Ltd. through a public bidding process, increasing its ownership from 52.49% to 67.77% [1] Group 1: Investment Details - The company invested 10 million yuan of its own funds to acquire the stake, excluding transaction fees and other costs [1] - The acquisition is aimed at enhancing the company's control over Xinjiang Qinxiong and accelerating the development of the Halahat Magnesite Mine [1]

Core Viewpoint - Sichuan Shuangma announced that on December 17, its controlling shareholder, Harmony Hengyuan, signed an agreement with LCOHC to transfer 48,786,912 shares (6.39% of total equity) of unrestricted circulating shares at a price of 22.32 yuan per share, totaling 1.089 billion yuan [1] Group 1 - The share transfer will increase Harmony Hengyuan's stake from 26.52% to 32.91%, while LCOHC's stake will decrease from 16.55% to 10.16% [1] - The transfer does not involve any reduction in holdings, and the controlling shareholder and actual controller will remain unchanged [1] - The transfer is subject to confirmation by the Shenzhen Stock Exchange and registration with China Securities Depository and Clearing Corporation, introducing some uncertainty regarding the outcome [1] Group 2 - The transferee has committed not to reduce the transferred shares within eighteen months after the transfer [1]

Core Viewpoint - Changchuan Technology (300604.SZ) plans to acquire a 33.3333% stake in Changchuan Manufacturing from the National Integrated Circuit Industry Investment Fund II through a public bidding process, aiming to increase its ownership to 100% [1] Group 1: Transaction Details - The transaction involves a public bidding process for the acquisition of a 33.3333% stake in Hangzhou Changchuan Intelligent Manufacturing Co., Ltd. [1] - The base price for the transaction is set at 46.287 million yuan, with the final bidding valuation not to be lower than the state-owned asset evaluation results [1] - Following the completion of this stake acquisition, the company's ownership in Changchuan Manufacturing will change from 66.6667% to 100% [1] Group 2: Corporate Governance - The fourth board meeting of the company approved the proposal for the public bidding to acquire the minority shareholder's stake in the subsidiary [1] - The board has requested authorization from the shareholders' meeting to handle matters related to this proposed acquisition and associated transactions [1]

Core Viewpoint - Watson Bio (300142.SZ) announced that its subsidiary, Yuxi Watson Biotechnology Co., Ltd., will acquire an 11.3043% stake from minority shareholder Huixiang Yuetai (Tianjin) Investment Partnership (Limited Partnership) for a price of 1.639 billion yuan, enhancing its control and decision-making efficiency over Yuxi Watson [1] Group 1 - The company will acquire an 11.3043% stake in Yuxi Watson from Huixiang Yuetai [1] - The transaction price for the stake is set at 1.639 billion yuan [1] - This acquisition will increase the company's ownership percentage in Yuxi Watson, thereby strengthening its control [1]

Core Viewpoint - Watson Bio announced the acquisition of a 2.4793% stake in its subsidiary Yuxi Watson from Tianjin Lanwo for a price of 359.4985 million yuan, which is expected to enhance control over Yuxi Watson and positively impact the company's performance for the current year, although there are uncertainties involved [1] Financial Summary - Yuxi Watson's projected revenue for 2024 is 2.664 billion yuan and net profit is 254 million yuan [1] - For the first nine months of 2025, Yuxi Watson reported revenue of 1.682 billion yuan and net profit of 269 million yuan [1] Transaction Details - The board meeting for the acquisition is scheduled for November 28, 2025, with payment due by November 30, 2025, and formal transfer of shares upon completion of business registration [1]

Group 1 - ST Zhongzhu announced the receipt of a share transfer agreement from Shenzhen Shenshang Holdings Group, where Shenshang plans to transfer 100% equity of its major shareholder, Shenzhen Landi Technology, to Suzhou Bubugao Investment Development for 30 million yuan [1] - After the transfer, Bubugao Investment will hold 380,172,862 shares of ST Zhongzhu, representing 19.08% of the total share capital [1] - Bubugao Investment stated that there are no plans to increase or decrease its stake in the company within the next 12 months, nor are there any major asset restructuring plans [1] Group 2 - On November 14, ST Zhongzhu announced that Qiongcheng Meihua Tenglong Qifei Investment Partnership intends to acquire 10.38% of the company's shares for 403 million yuan [2] - Qiongcheng Meihua Tenglong Qifei Investment Partnership, which is 80% owned by Wu Shichun, expressed confidence in the company's future development prospects and investment value [2] - The partnership aims to actively exercise shareholder rights to improve the company's operations, asset quality, and sustainable profitability [2]